Dupilumab Effective in Atopic Dermatitis Tx
(HealthDay News) The fully monoclonal antibody that blocks interleukin-4 and interleukin-13, dupilumab, is effective in atopic dermatitis, according to research published in the July 10 issue of the New England Journal of Medicine.
Lisa A. Beck, MD, from the University of Rochester Medical Center in New York, conducted trials involving adults with moderate-to-severe atopic dermatitis despite receiving topical glucocorticoids and calcineurin inhibitors. Two four-week trials and one 12-week trial assessed dupilumab as monotherapy, while another four-week trial assessed it in combination with topical glucocorticoids.
The researchers found that dupilumab resulted in rapid, dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome in the four-week monotherapy studies. These findings were reproduced and extended in the 12-week dupilumab monotherapy study, with a 50% reduction in the Eczema Area and Severity Index score (EASI-50) seen in 85% of patients in the dupilumab group and 35% of those in the placebo group. In addition, significantly more patients in the dupilumab group had a score of 0–1 on the investigator's global assessment (P<0.001) and a decrease in pruritus scores (P<0.001). In the combination study, the criterion for EASI-50 was met by 100% of patients in the dupilumab group and 50% in the placebo group (P=0.002).
"Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity," the authors write. "Side-effect profiles were not dose-limiting."
The study was funded by Regeneron Pharmaceuticals and Sanofi, the manufacturers of dupilumab.